PARAGON-HF — Why We Do Randomized, Controlled Clinical Trials

Patients with heart failure and preserved ejection fraction have high morbidity and mortality, as well as reduced quality of life, and there are no approved therapies. The complex pathophysiological mechanisms contributing to this condition have made therapeutic development difficult. The PARAMOUNT (Prospective Comparison of ARNI [angiotensin receptor–neprilysin inhibitor] with ARB [angiotensin-receptor blocker] on Management of Heart Failure...